View More
In this concise video, review recommendations for therapeutic drug monitoring of TNF-α inhibitor therapy and hear expert discussion of key data informing second-line treatment decisions of moderate to severe UC and CD following TNF-α inhibitor failure.
Bruce E. Sands, MD, MS
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Released: May 24, 2021
Expired:
No longer available for credit
Learn about current guideline recommendations for therapeutic drug monitoring of TNF-α inhibitor therapy and review key data informing second-line treatment decisions of moderate to severe UC and CD following TNF-α inhibitor failure.
Bruce E. Sands, MD, MS
Released: May 24, 2021
My take on TDM for patients receiving TNF-α inhibitors for IBD.
Bruce E. Sands, MD, MS
Released: June 3, 2021
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.